<DOC>
	<DOCNO>NCT01204164</DOCNO>
	<brief_summary>This multicenter , open-label , dose escalation Phase 1 study .</brief_summary>
	<brief_title>Phase 1 Study TG02 Citrate Patients With Advanced Hematological Malignancies</brief_title>
	<detailed_description>This multicenter , open-label , dose escalation , Phase 1/1b study . For Parts 1 , 2 , 3 study , primary objective determine high dose TG02 citrate safely give patient different type hematological malignancy . For Part 4 , primary objective evaluate safety tolerability once-weekly dose maximum-tolerated dose/ Recommended Phase 2 Dose TG02 combination carfilzomib . This study consist four part : - Part 1 : single agent TG02 acute leukemia patient - Part 2 : single agent TG02 multiple myeloma patient - Part 3 : TG02 combination carfilzomib multiple myeloma patient - Part 4 : TG02 combination carfilzomib carfilzomib refractory multiple myeloma patient .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Part 1 Relapsed AML , ALL , CML blast crisis , MDS 65+ yr AML eligible standard frontline chemo Interval prior treatment time study drug least 5 halflives cytotoxic/ noncytotoxic agent . Persistent clinically significant toxicity prior chemo ≤ Grd 1 ECOG PS 02 Lab value : Cr ≤ 2X ULN ALT and/or AST ≤2.5 X ULN Total bilirubin ≤1.5 X ULN unless consider due Gilbert 's syndrome Negative pregnancy test Can take oral med Part 2 Relapsed multiple myeloma . At least ≥1 line therapy progress ≥1 prior therapy Measurable disease define least one following : Serum M ≥500 mg/dL Urine M ≥200 mg per 24hr Involved FLC ≥10 mg/dL abnormal FLC ratio serum ( &lt; 0.26 &gt; 1.65 ) Measurable soft tissue plasmacytoma Persistent clinically significant toxicity prior chemo ≤ Grd 1 ECOG PS 02 Lab value : ANC &gt; 1000/mm3 Platelets ≥50,000/mm3 Cr ≤2X ULN ALT and/or AST ≤2.5X ULN Total bilirubin ≤1.5X ULN , unless consider due Gilbert 's syndrome Negative pregnancy test Can take oral med Part 3 Measurable disease define least one following : Serum M ≥500 mg/dL Urine M protein ≥200 mg per 24hr Involved FLC level ≥10 mg/dL abnormal FLC ratio serum ( &lt; 0.26 &gt; 1.65 ) Meet least one criterion : . ≥2 prior therapy include proteasome inhibitor immunomodulatory agent ( IMiD ) b . ≥1 prior therapy one follow abnormality : 17p del , p53 , 1q amp , 1p del , ( 4 ; 14 ) Interval prior treatment time study drug least 5 halflives 3 wks , ever short , noncytotoxic agent Persistent clinically significant toxicity prior chemo ≤ Grd 1 Grd 2 neuropathy without pain ECOG PS 02 Lab value : ANC &gt; 1000/mm3 independent GCSF Platelets ≥50,000/mm3 independent transfusion MDRD calculate measure CrCl ≥30 mL/min ALT and/or AST ≤3X ULN Total bilirubin ≤2X ULN , unless consider due Gilbert 's syndrome Negative pregnancy test Can take oral med Part 4 Measurable disease define least one following : Serum M ≥500 mg/dL Urine M protein ≥200 mg per 24hr Involved FLC level ≥10 mg/dL abnormal FLC ratio serum ( &lt; 0.26 &gt; 1.65 ) Received prior therapy include : a. bortezomib b. IMiD c. carfilzomib . Demonstrated disease progression within 60d completion carfilzomib therapy Interval prior treatment time study drug least 5 halflives 3 wks , ever short , noncytotoxic agent . Persistent clinically significant toxicity prior chemo ≤ Grd 1 , Grd 2 neuropathy without pain . ECOG PS 02 Lab value : ANC &gt; 1000/mm3 independent GCSF Platelets ≥50,000/mm3 independent transfusion MDRD calculate measure CrCl ≥30 mL/min ALT and/or AST ≤3X ULN Total bilirubin ≤2X ULN , unless consider due Gilbert 's syndrome Negative pregnancy test Can take oral med Parts 1 2 Previous allogenic hematopoietic transplant within 90 Concurrent severe uncontrolled medical disease would compromise safety compromise ability patient complete study Prolonged QTC interval &gt; 450ms Symptomatic CNS metastases Known HIV AIDS Actively treat second malignancy Pregnant nursing woman Part 3 Multiple myeloma IgM subtype , POEMS , plasma cell leukemia Corticosteroids discontinue ≥7 day initiate therapy Previous chemo within 2 wks Hx ventricular arrhythmia symptomatic conduction abnormality within 12m CHF , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention , myocardial infarction within 6m Prolonged QTc interval ( male &gt; 450ms , female &gt; 470ms ) Previous allogeneic hematopoietic transplant within 90 day study enrollment , Active GVHD require treatment . Concurrent severe uncontrolled medical disease would compromise safety compromise ability patient complete study Symptomatic CNS metastases Known HIV AIDS Prior 2nd malignancy , except nonmelanoma skin cancer , completely resect cervical prostate cancer ( PSA le equal 0.1 ng/ml ) , cancer subject receive curative therapy least 3 yrs prior study entry Treatmentrelated MDS Significant neuropathy ( Grd 34 Grd 2 pain ) time 1st dose Primary AL amyloidosis Pleural effusion require thoracentesis ascites require paracentesis Pregnant nursing woman Part 4 Multiple myeloma IgM subtype , POEMS , plasma cell leukemia Previous chemo within 2 wks Hx ventricular arrhythmia symptomatic conduction abnormality within 12m CHF , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention , myocardial infarction within 6m Prolonged QTc interval ( male &gt; 450ms , female &gt; 470ms ) Previous allogeneic hematopoietic transplant within 90 day . Active GVHD require treatment Concurrent severe uncontrolled medical disease would compromise safety compromise ability patient complete study Symptomatic CNS metastases Known HIV AIDS Prior 2nd malignancy , except nonmelanoma skin cancer , completely resect cervical prostate cancer ( PSA le equal 0.1 ng/ml ) , cancer subject receive curative therapy least 3 yrs prior study entry Treatmentrelated MDS Significant neuropathy ( Grd 34 Grd 2 pain ) time 1st dose Primary AL amyloidosis Pleural effusion require thoracentesis ascites require paracentesis Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>MDS</keyword>
	<keyword>CML blast crisis</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Carfilzomib refractory</keyword>
</DOC>